Plain-English translation of NCT05187091 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a specialized type of radiation therapy called swallowing-sparing IMRT, which is designed to treat head and neck cancer while protecting the parts of your throat and neck that help you swallow safely. The goal is to see whether this newer planning technique causes fewer and less severe swallowing problems compared to standard radiation therapy, while still treating your cancer effectively.
Many people treated with radiation for head and neck cancer experience serious, long-lasting difficulty swallowing and risk of food going into the lungs—side effects that greatly affect quality of life. This trial exists to find out whether protecting the swallowing-related structures during radiation planning can reduce these devastating complications.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard radiation therapy or the new swallowing-sparing radiation technique, both combined with chemotherapy. You'll have clinic visits weekly during your 6–7 weeks of radiation treatment, then return for follow-up visits at 3, 6, 12, and 24 months after treatment ends, and annually thereafter up to 5 years. At these visits, you'll complete questionnaires about your swallowing ability, undergo swallowing tests, and have imaging or blood work to monitor your cancer and any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
India